<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503047</url>
  </required_header>
  <id_info>
    <org_study_id>HULP-2297</org_study_id>
    <nct_id>NCT01503047</nct_id>
  </id_info>
  <brief_title>Conjugated Linoleic Acid (1:1 Isomer Mixture) Intake in Overweight People</brief_title>
  <acronym>CLA</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tonalin(R)Intake in Overweight People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz</source>
  <brief_summary>
    <textblock>
      The aim of the study was to examine the effects and safety of 3 g of a 1:1 mix of c9-t11 and
      t10-c12 (Tonalin®) on weight control and body composition in healthy overweight individuals
      who maintained their normal dietary and exercise patterns.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body composition(DXA)</measure>
    <time_frame>0, 3, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>anthropometric parameters</measure>
    <time_frame>0,1, 2, 3, 4, 5 and 6 month</time_frame>
    <description>paramteres measured were: Weight, Height and Waist Circunference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameters</measure>
    <time_frame>0, 3 and 6 month</time_frame>
    <description>lipid profile glucose, insulin CR-P PAI-1 adiponectin, leptin creatinine GPT and GOT transaminases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-Index</measure>
    <time_frame>0, 3, 6 month</time_frame>
    <description>insulin sensitivity index was calculated using the formula: HOMA-IR = fasting glucose (mmol/l)/fasting immunoreactive insulin (mU/ml)/22•5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>CLA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tonalin®</intervention_name>
    <description>Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)</description>
    <arm_group_label>CLA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 30-55 years

          -  grade II overweight (BMI≥27 but &lt;30 kg/m2)

          -  not to be adhered to any calorie restriction diet

          -  not to be taking any weight control medication or have lost more than 5 kg in the
             three months prior to the study

        Exclusion Criteria:

          -  suffering of serious concomitant disease such as diabetes mellitus type II, metabolic
             syndrome (according to the criteria of the Adult Treatment Panel III), cancer, kidney
             disease, HIV, tuberculosis, cardiovascular disease, chronic obstructive pulmonary
             disease, eating disorders.

          -  having undergone bariatric surgery and/or intestinal resection

          -  breastfeeding and pregnancy.

          -  not to give their signed, informed consent to be included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.idipaz.es</url>
    <description>institution web</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <last_update_submitted>January 2, 2012</last_update_submitted>
  <last_update_submitted_qc>January 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz</investigator_affiliation>
    <investigator_full_name>Ignacio Galicia</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

